Reaffirmed: ADMA Biologics (NASDAQ:ADMA) “Buy” Rating Kept by Analysts at Ladenburg; $7.5000 Target in Place

June 13, 2018 - By Kenneth Lin

ADMA Biologics, Inc. (NASDAQ:ADMA) Logo

Investors sentiment decreased to 2.86 in 2018 Q1. Its down 0.14, from 3 in 2017Q4. It dropped, as 1 investors sold ADMA Biologics, Inc. shares while 6 reduced holdings. 11 funds opened positions while 9 raised stakes. 15.52 million shares or 0.06% less from 15.53 million shares in 2017Q4 were reported.

Royal Savings Bank Of Canada holds 0% of its portfolio in ADMA Biologics, Inc. (NASDAQ:ADMA) for 4,000 shares. Broadfin Capital Ltd Liability Company reported 720,529 shares or 0.52% of all its holdings. Jpmorgan Chase And invested in 0% or 39,491 shares. Aisling Capital Ltd Llc invested in 2.96% or 3.61M shares. Geode Capital Management Limited Liability Company holds 112,000 shares or 0% of its portfolio. Citadel Advsrs Limited Liability Corporation stated it has 12,890 shares or 0% of all its holdings. Moreover, Morgens Waterfall Vintiadis And has 1.05% invested in ADMA Biologics, Inc. (NASDAQ:ADMA) for 300,000 shares. Vanguard Grp Inc has 0% invested in ADMA Biologics, Inc. (NASDAQ:ADMA) for 886,987 shares. Perceptive Advsrs Ltd Liability Co accumulated 3.82M shares or 0.49% of the stock. Financial Bank Of America Corp De owns 5,188 shares. Highbridge Cap Mngmt Ltd Liability stated it has 0.02% of its portfolio in ADMA Biologics, Inc. (NASDAQ:ADMA). Bluecrest Management Ltd stated it has 23,568 shares or 0% of all its holdings. 683 Cap Ltd Liability holds 0.33% or 805,000 shares in its portfolio. Advisory Serv Lc owns 1,700 shares. State Bank Of Mellon reported 0% in ADMA Biologics, Inc. (NASDAQ:ADMA).

Since June 8, 2018, it had 5 insider purchases, and 0 insider sales for $744,504 activity. $23,900 worth of ADMA Biologics, Inc. (NASDAQ:ADMA) was bought by LENZ BRIAN on Friday, June 8. On Friday, June 8 RICHMAN ERIC I bought $24,999 worth of ADMA Biologics, Inc. (NASDAQ:ADMA) or 5,230 shares. Grossman Jerrold B also bought $250,004 worth of ADMA Biologics, Inc. (NASDAQ:ADMA) on Friday, June 8. 73,222 shares were bought by Grossman Adam S, worth $350,001.

ADMA Biologics (NASDAQ:ADMA) Rating Reaffirmed

The firm has just set a price target of $7.5000 on ADMA Biologics (NASDAQ:ADMA) shares. This is 56.58 % from the current stock price. In analysts report issued on Wednesday, 13 June, Ladenburg reiterated their “Buy” rating on shares of ADMA.

The stock decreased 1.24% or $0.06 during the last trading session, reaching $4.79. About 261,424 shares traded or 54.89% up from the average. ADMA Biologics, Inc. (NASDAQ:ADMA) has risen 49.86% since June 14, 2017 and is uptrending. It has outperformed by 37.29% the S&P500.

Analysts await ADMA Biologics, Inc. (NASDAQ:ADMA) to report earnings on August, 10. They expect $-0.35 earnings per share, up 36.36 % or $0.20 from last year’s $-0.55 per share. After $-0.35 actual earnings per share reported by ADMA Biologics, Inc. for the previous quarter, Wall Street now forecasts 0.00 % EPS growth.

ADMA Biologics, Inc., a biopharmaceutical company, develops, makes, and markets specialty plasma biologics for the treatment of immune deficiencies and infectious diseases. The company has market cap of $216.00 million. The Company’s lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical study for the treatment of primary immune deficiency disease. It currently has negative earnings. The firm also operates source plasma collection facilities in Norcross and Marietta, Georgia.

More notable recent ADMA Biologics, Inc. (NASDAQ:ADMA) news were published by: Nasdaq.com which released: “ADMA Biologics Announces Closing of $40M Public Offering” on June 12, 2018, also Streetinsider.com with their article: “After-Hours Stock Movers 06/07: (ZUMZ) (DOCU) (SFIX) Higher; (MVIS) (ITI) (ADMA) Lower (more…)” published on June 07, 2018, Globenewswire.com published: “ADMA Biologics Announces Pricing of Public Offering of Common Stock” on June 08, 2018. More interesting news about ADMA Biologics, Inc. (NASDAQ:ADMA) were released by: Globenewswire.com and their article: “ADMA Biologics Granted US Patent for Treating Respiratory Infections” published on May 16, 2018 as well as Benzinga.com‘s news article titled: “Benzinga’s Daily Biotech Pulse: vTv Swoons On Failed Alzheimer’s Trial, Regenxbio Gets FDA Fast Track For RGX-111” with publication date: June 13, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: